A Phase Ib/II Study of Mocetinostat plus Brentuximab Vedotin in Patients with Recurrent or Persistent Hodgkin Lymphoma

Full Title

Phase IB/II study of Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma


The purpose of this study is to find the highest dose of the investigational drug mocetinostat that can be given safely with brentuximab vedotin in patients with Hodgkin lymphoma that has come back despite prior therapy. Mocetinostat works by inhibiting an enzyme involved in cancer growth called histone deacetylase. It is taken orally (by mouth).

Brentuximab has two parts: one (an antibody) that attaches to a protein on the surface of cancer cells called CD30, and another (an anticancer drug called monomethyl auristatin E) that kills the cancer. It is already approved for treating Hodgkin lymphoma and is given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have Hodgkin lymphoma that has stopped responding to at least two prior regimens of chemotherapy or which came back after a stem cell transplant.
  • Patients must have Hodgkin lymphoma that contains the CD30 protein.
  • At least 3 weeks must pass between completion of previous treatment and entry into the study.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Alison Moskowitz at 212-639-4839.